Get the Stockscreener App
1.10
4.76%
0.05
Pre-market:
1.10
Caribou Biosciences Inc stock is traded at $1.10, with a volume of 1.38M.
It is up +4.76% in the last 24 hours and up +49.66% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$1.05
Open:
$1.06
24h Volume:
1.38M
Relative Volume:
1.34
Market Cap:
$102.31M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-0.7534
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
+40.52%
1M Performance:
+49.66%
6M Performance:
-43.88%
1Y Performance:
-64.86%
1-Day Range:
$1.01
$1.12
1-Week Range:
$0.7691
$1.12
52-Week Range:
$0.66
$3.19
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.10 | 72.80M | 34.48M | -102.07M | -104.90M | -1.46 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences - Barchart.com
Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class ActionCRBU - ACCESS Newswire
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates - MSN
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $9.33 - Defense World
Cantor Fitzgerald Analysts Lower Earnings Estimates for CRBU - Defense World
Dimensional Fund Advisors LP Sells 321,867 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Barclays PLC Grows Stock Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences Reports Q1 2025 Financial Results - TipRanks
Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU - ACCESS Newswire
Investors who lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class ActionCRBU - ACCESS Newswire
Caribou Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU - ACCESS Newswire
Caribou Biosciences (CRBU) Receives a Buy from Bank of America Securities - The Globe and Mail
Shareholders that Lost Money on Caribou Biosciences, Inc. (CRBU) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
RBC Lowers Price Target on Caribou Biosciences to $10 From $11, Keeps Outperform, Speculative Risk - marketscreener.com
Envestnet Asset Management Inc. Grows Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Comparing Invizyne Technologies (NASDAQ:IZTC) and Caribou Biosciences (NASDAQ:CRBU) - Defense World
Ratio Revelations: Caribou Biosciences Inc (CRBU)’s Financial Metrics in the Spotlight - DWinneX
Leading CRISPR Company Caribou Biosciences to Reveal Latest Pipeline Updates at Major Healthcare Conference - Stock Titan
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference - The Manila Times
Caribou Biosciences (CRBU) to Release Quarterly Earnings on Tuesday - Defense World
Levi & Korsinsky Notifies Shareholders of Caribou Biosciences, Inc.(CRBU) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Investors Can Still File Late Claims for Caribou Biosciences $3.9M Settlement Payouts - TradingView
HC Wainwright Issues Optimistic Forecast for CRBU Earnings - Defense World
Caribou Biosciences Inc [CRBU] Records 200-Day SMA of $1.6979 - knoxdaily.com
Taking the lead: Caribou Biosciences Inc (CRBU) - Sete News
Caribou Biosciences Investors Drop Suit Over Cell Therapy, Cash - Bloomberg Law News
CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou B - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Is Caribou Biosciences Inc (CRBU) worth investing in despite its undervalued state? - uspostnews.com
Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Caribou Biosciences Inc (NASDAQ: CRBU) -0.30% Decline Turns Investors Away - Stocksregister
Geode Capital Management LLC Sells 58,048 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
H.C. Wainwright cuts Caribou Biosciences stock target to $3 By Investing.com - Investing.com India
H.C. Wainwright cuts Caribou Biosciences stock target to $3 - Investing.com Australia
Caribou Biosciences (CRBU) Target Price Cut Amid Strategic Shift - GuruFocus
Quarterly Snapshot: Quick and Current Ratios for Caribou Biosciences Inc (CRBU) - DWinneX
Caribou Biosciences Inc (CRBU) Stock: A Year of Decreases and Increases - investchronicle.com
Caribou Biosciences Inc (CRBU) receives an In-line rating from Evercore ISI - knoxdaily.com
Caribou Biosciences (CRBU) Target Price Cut Amid Strategic Shift | CRBU Stock News - GuruFocus
Caribou Biosciences (CRBU) Sees Price Target Cut Amid Strategic - GuruFocus
Russell Investments Group Ltd. Boosts Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Lost Money on Caribou Biosciences, Inc. (CRBU)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies - MedCity News
Caribou Biosciences (CRBU) Restructures, Focuses on Key Oncology Programs - GuruFocus
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):